---
figid: PMC7396149__gr4_lrg
figtitle: Immunosuppressive drugs for corneal transplantation and their sites of action
  in the immune system
organisms:
- Human immunodeficiency virus 1
- Severe acute respiratory syndrome coronavirus 2
- Human gammaherpesvirus 4
- Coronaviridae
- Human immunodeficiency virus
- Human papillomavirus
- Middle East respiratory syndrome-related coronavirus
- Human alphaherpesvirus 3
- Porcine circovirus 2
- Betapolyomavirus hominis
- Peanut clump virus
- Porcine circovirus
- Porcine endogenous retrovirus
- Macacine betaherpesvirus 3
- Cercopithecine alphaherpesvirus 9
- Baboon cytomegalovirus
- Bos taurus
- Oryctolagus cuniculus
- Canis lupus familiaris
- Sus scrofa
- Ovis aries
- Equus caballus
- Sus scrofa domesticus
- Homo sapiens
- Macaca mulatta
- Pan troglodytes
- Papio hamadryas
- Hylobates sp.
- Toxoplasma gondii
- Pieris brassicae
- Strongyloides stercoralis
- Dictyostelium medium
- Mus musculus
- Rattus norvegicus
- Cavia porcellus
- Mycobacterium tuberculosis
- Treponema pallidum
- Gallus gallus
- Pneumocystis jirovecii
- NA
- NA
- NA
organisms_ner:
- Gallus gallus
- Mus musculus
- Canis lupus familiaris
- Rattus norvegicus
- Ovis aries
- Oryctolagus cuniculus
- Pan troglodytes
- Cavia porcellus
- Homo sapiens
- Bos taurus
- Equus caballus
- Sus scrofa
- Macaca mulatta
- Drosophila melanogaster
pmcid: PMC7396149
filename: gr4_lrg.jpg
figlink: pmc/articles/PMC7396149/figure/fig4/
number: F4
caption: 'Immunosuppressive drugs for corneal transplantation and their sites of action
  in the immune system. There are various kinds of immunosuppressive drugs that have
  been used in high-risk corneal allotransplantation or pig-to-non-human primate (NHP)
  corneal transplantation experiments. Most of these drugs target interactions between
  T cells and antigen-presenting cells or intracellular pathway involved in T cell
  activation. Drugs highlighted with a red-colored text are potential candidates for
  corneal xenotransplantation clinical trials, of which efficacy and safety have been
  proven in pig-to-NHP corneal transplantation studies. Abbreviations: AP-1: activating
  protein-1, APC: antigen presenting cell, CS: corticosteroid, CsA: cyclosporine A,
  CTLA: cytotoxic T lymphocyte antigen, FKBP: FK506-binding protein, G1: cell cycle
  gap phase 1, G2: cell cycle gap phase 2, IVIG: intravenous immunoglobulin, M: cell
  cycle mitosis phase, MHC: major histocompatibility complex, MPA: mycophenolic acid,
  mTOR: mammalian target of rapamycin, NFAT: nuclear factor of activated T cells,
  NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells, TCR: T cell
  receptor, S: cell cycle synthesis phase. . (For interpretation of the references
  to color in this figure legend, the reader is referred to the Web version of this
  article.)'
papertitle: 'Corneal xenotransplantation: Where are we standing?.'
reftext: Chang Ho Yoon, et al. Prog Retin Eye Res. 2021 Jan;80:100876-100876.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.966923
figid_alias: PMC7396149__F4
figtype: Figure
redirect_from: /figures/PMC7396149__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7396149__gr4_lrg.html
  '@type': Dataset
  description: 'Immunosuppressive drugs for corneal transplantation and their sites
    of action in the immune system. There are various kinds of immunosuppressive drugs
    that have been used in high-risk corneal allotransplantation or pig-to-non-human
    primate (NHP) corneal transplantation experiments. Most of these drugs target
    interactions between T cells and antigen-presenting cells or intracellular pathway
    involved in T cell activation. Drugs highlighted with a red-colored text are potential
    candidates for corneal xenotransplantation clinical trials, of which efficacy
    and safety have been proven in pig-to-NHP corneal transplantation studies. Abbreviations:
    AP-1: activating protein-1, APC: antigen presenting cell, CS: corticosteroid,
    CsA: cyclosporine A, CTLA: cytotoxic T lymphocyte antigen, FKBP: FK506-binding
    protein, G1: cell cycle gap phase 1, G2: cell cycle gap phase 2, IVIG: intravenous
    immunoglobulin, M: cell cycle mitosis phase, MHC: major histocompatibility complex,
    MPA: mycophenolic acid, mTOR: mammalian target of rapamycin, NFAT: nuclear factor
    of activated T cells, NF-κB: nuclear factor kappa-light-chain-enhancer of activated
    B cells, TCR: T cell receptor, S: cell cycle synthesis phase. . (For interpretation
    of the references to color in this figure legend, the reader is referred to the
    Web version of this article.)'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CTLA4
  - CD88
  - CD28
  - CD40LG
  - CD40
  - CS
  - IL2
  - APC
  - MTOR
  - fc
  - Hspa9
  - Ercc8
  - Ctla4
  - Cd80
  - Cd28
  - Cd40lg
  - Cd40
  - Cs
  - Jun
  - App
  - H2-Ab1
  - Nfkb1
  - Il2
  - Trav6-3
  - H2
  - Apc
  - Gabrg2
  - Fkbp1a
  - Mtor
  - Ms4a1
  - Il2ra
  - ALB
  - CD80
  - JUN
  - MS4A1
  - IL2RA
  - Nfat5
  - Ccne1
  - RECEPTOR
  - NFKB2
  - PROC
  - IL4
  - MYH1
  - FKBP1A
  - CWC27
  - PPIA
  - PPIB
  - PPIC
  - PPID
  - PPIE
  - PPIF
  - PPIH
  - PPIL1
  - PPIL2
  - PPIL3
  - PPIL4
  - PPIL6
  - PPWD1
  - PPIAL4A
  - PPIAL4C
  - PPIAL4G
  - ERCC8
  - CSH1
  - HSPA9
  - NFATC1
  - NFATC2
  - NFATC3
  - NFATC4
  - NFAT5
  - FOS
  - FOSB
  - JUNB
  - JUND
  - APP
  - SUCLA2
  - NFKB1
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - HLA-C
  - WARS1
  - KRT20
  - ISG20
  - LOC505306
  - TARP
  - TNFRSF13B
  - Sh
  - Prosbeta7
  - NFAT
  - cs
  - AP-1gamma
  - Jra
  - kay
  - ab
  - Appl
  - Dif
  - dl
  - Rel
  - Tcr
  - Myo61F
  - Mhc
  - zip
  - Apc2
  - Axn
  - Fs(3)Apc
  - LanB2
  - anon-70Db
  - anon-70Dc
  - Fkbp12
  - CycE
  - cyc
  - Tor
  - TCR
  - Tacrolimus
  - Purine
---
